DURHAM, N.C., August 20, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced that it has become an Olink® Certified Service Provider (CSP), making it the first Olink CSP in the Carolinas and one of only three in the Southeastern United States.
For MedPharm’s clients, the addition of Olink technology creates opportunities to combine proteomic data with established disease models using reconstructed and ex vivo human tissues. This integrated approach can provide a more comprehensive view of therapeutic activity, helping researchers investigate biological responses and potential mechanisms of action in human-relevant models.
“Becoming an Olink Certified Service Provider extends MedPharm into targeted, multiplex protein biomarker analysis for the first time,” said Jon Lenn, Ph.D., Chief Scientific Officer, MedPharm. “We are the only contract research organization with Certified Service Provider status in the Carolinas, and this platform lets us bring that capability to sponsors directly rather than through a third party. This certification is also the first step in a broader plan to expand MedPharm’s capabilities as a contract research organization, supporting clinical trial sample analysis and translational models that support clinical development.”
The Olink platform is powered by Proximity Extension Assay (PEA) technology, a highly sensitive method that uses dual antibody recognition of target proteins with a DNA-based readout. PEA enables precise measurement of protein biomarkers from sample volumes as small as 1 µL, supporting both absolute and relative protein measurements across low- and high-abundance targets.
With established operations in both the US and UK, together with its partnership network in Belgium, MedPharm is positioned to support clients internationally and expand its proteomic and human-relevant testing capabilities.
[ends]
About MedPharm
MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With its 2024 merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development and formulation to large batch commercial manufacturing and distribution.
For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 110,000 sq. ft. state-of-the-art manufacturing facility in Durham, North Carolina. For more information, visit medpharm.com or follow us on LinkedIn.
Media Contacts:
Sadie Smith, Marketing and Events Coordinator
Miles Fisher-Pollard, Orientation Marketing
